Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 7,773 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

NCT07024823
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
AZD4248, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

NCT02174627
View directory record Official record
Conditions
Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

NCT06097273
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
8,061 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
146
States / cities
Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 17, 2026, 2:36 AM EDT
Recruiting Phase 2 Interventional

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

NCT06480383
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
ITI-1284 10 mg, ITI-1284 20 mg, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
Not listed
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Glendale, California • Imperial, California • Lemon Grove, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

NCT03919409
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-161, TS-161 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial

NCT01796678
View directory record Official record
Conditions
Vaso-occlusive Pain Episodes
Interventions
Arginine, Placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
3 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

NCT05573685
View directory record Official record
Conditions
Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
Interventions
DiNaMo Study App, Placebo App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

NCT00090064
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Midomafetamine HCl, Lactose placebo pill, Therapy
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

Cognitive Training and tDCS for Children With FASD

NCT03361293
View directory record Official record
Conditions
Fetal Alcohol Spectrum Disorders
Interventions
Active tDCS, Cognitive training, Sham tDCS
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years to 16 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

NCT04167514
View directory record Official record
Conditions
Graft Versus Host Disease (GVHD)
Interventions
Alpha-1 antitrypsin (AAT), Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Recruiting Phase 2 Interventional

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
ABBV-CLS-628, Placebo
Drug
Lead sponsor
Calico Life Sciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Not listed Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00004064
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
oregovomab
Biological
Lead sponsor
AltaRex
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
15
States / cities
Newport Beach, California • Fort Myers, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
74
States / cities
Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

NCT00001034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 2:36 AM EDT
Not yet recruiting Phase 1 Interventional

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT05852587
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

NCT01958021
View directory record Official record
Conditions
Advanced, Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
73
States / cities
Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NCT00002071
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 2:36 AM EDT
Terminated Phase 2 Interventional

Movantik for Opioid-Related Esophageal Disorders

NCT02998606
View directory record Official record
Conditions
Opioid-Induced Disorders, Esophagus Disorder
Interventions
Naloxegol, Placebo Oral Capsule
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 17, 2026, 2:36 AM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

NCT00040404
View directory record Official record
Conditions
Parkinson Disease
Interventions
CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg, Placebo Comparator
Drug · Other
Lead sponsor
Cephalon
Industry
Eligibility
30 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
96
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 17, 2026, 2:36 AM EDT
Not listed Phase 4 Interventional

Nicotine Treatment of Impulsivity in Parkinson's Disease

NCT01216904
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine patch, placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

NCT00234832
View directory record Official record
Conditions
Obesity
Interventions
Sibutramine hydrochloride, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
55 Years and older
Enrollment
10,777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2010 · Synced Oct 17, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

NCT02214121
View directory record Official record
Conditions
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Interventions
Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 17, 2026, 2:36 AM EDT